| Identification | Back Directory | [Name]
1H-Pyrazole-4-carboxamide, 3-[2-(3,5-dimethoxyphenyl)ethynyl]-5-(methylamino)-1-[(3S)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]- | [CAS]
2211082-53-8 | [Synonyms]
ICP-192
Gunagratinib
Gunagratinib(ICP-192)
1H-Pyrazole-4-carboxamide, 3-[2-(3,5-dimethoxyphenyl)ethynyl]-5-(methylamino)-1-[(3S)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]- | [Molecular Formula]
C22H25N5O4 | [MOL File]
2211082-53-8.mol | [Molecular Weight]
423.46 |
| Chemical Properties | Back Directory | [Boiling point ]
717.2±60.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
14.76±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1]. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2]. | [IC 50]
FGFR | [References]
[1] Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.
[2] Jisong Cui, et al. Method for treating head and neck cancer. WO2023088105A1. 2022-11-03 |
|
|